Summit Therapeutics Inc. (SMMT) Gets $2B AZ Equity Investment, Inks Clinical Collaboration

Summit Therapeutics will receive a $2.0B AstraZeneca equity investment in convertible preferred shares at an implied $18.36, subject to closing, and entered a clinical collaboration on ivonescimab with sone-ve and plans to test combos with other AZ cancer medicines.Material DetailsContext by AI Ana…